Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment.
Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment.
复制标题
对表皮生长因子受体（EGFR）的免疫反应及其在癌症治疗中的应用。
DOI：
10.3389/fphar.2016.00405
复制
发表时间：
2016
影响因子：
5.6
通讯作者：
Fujimoto Y
中科院分区：
文献类型：
--
作者：
Sasada T;Azuma K;Ohtake J;Fujimoto Y
表皮生长因子受体 (EGFR) 是属于 ErbB/HER 癌基因家族的原型细胞表面受体。据报道，EGFR 的过度表达或体细胞突变在各种类型的上皮癌的肿瘤发生中发挥重要作用。因此，针对 EGFR 的特异性阻断抗体或抑制剂已被开发用于治疗 EGFR 相关肿瘤。对 HER2（ErbB/HER 癌基因家族的另一种分子）的免疫反应已得到充分研究，但目前仅获得有关癌症中对 EGFR 的免疫反应的有限信息。在这篇综述中，我们总结了现有数据，并讨论了抗 EGFR 免疫反应和 EGFR 介导的免疫调节在癌症中的潜在临床重要性。多项证据表明，针对 EGFR 的细胞和体液免疫反应可能可用作针对 EGFR 相关肿瘤的癌症治疗的标记物和/或靶点。此外，最近的研究表明，EGFR 介导的信号传导在肿瘤细胞中免疫检查点分子程序性死亡配体 1 (PD-L1) 表达的调节中发挥着关键作用。需要进一步的研究来阐明抗 EGFR 免疫反应和 EGFR 介导的免疫调节对癌症治疗临床应用的影响。
Epidermal growth factor receptor (EGFR) is a prototypic cell-surface receptor belonging to the ErbB/HER onocogene family. Overexpression or somatic mutations of EGFR have been reported to play an important role in tumorigenesis in various types of epithelial cancers. Therefore, targeting of EGFR with specific blocking antibodies or inhibitors have been developing for treatment for EGFR-associated tumors. Immune responses to HER2, another molecule of the ErbB/HER onocogene family, have been well studied, but only limited information on the immune responses to EGFR in cancer has been currently available. In this review, we have summarized the available data and discussed potential clinical importance of the anti-EGFR immune responses and EGFR-mediated immune regulation in cancer. Several lines of evidence suggest that cellular and humoral immune responses to EGFR might be useful as a marker and/or target for cancer therapy against EGFR-associated tumors. In addition, recent studies suggest the critical roles of EGFR-mediated signaling in regulation of expression of an immune checkpoint molecule, programmed death-ligand 1 (PD-L1) in tumor cells. Further studies are warranted to clarify the impact of the anti-EGFR immune responses and EGFR-mediated immunomodulation for clinical application for cancer treatment.
登录
查看更多内容
DOI：
10.1097/cji.0b013e3181b8f421
发表时间：
2010-01
期刊：
Journal of immunotherapy (Hagerstown, Md. : 1997)
影响因子：
--
作者：
Andrade Filho PA;López-Albaitero A;Gooding W;Ferris RL
通讯作者：
Ferris RL
DOI：
10.1158/1078-0432.ccr-15-3101
发表时间：
2016-09-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Gainor JF;Shaw AT;Sequist LV;Fu X;Azzoli CG;Piotrowska Z;Huynh TG;Zhao L;Fulton L;Schultz KR;Howe E;Farago AF;Sullivan RJ;Stone JR;Digumarthy S;Moran T;Hata AN;Yagi Y;Yeap BY;Engelman JA;Mino-Kenudson M
通讯作者：
Mino-Kenudson M
影响因子：
11.2
作者：
Guo G;Gong K;Wohlfeld B;Hatanpaa KJ;Zhao D;Habib AA
通讯作者：
Habib AA
HLA-A2（+）癌症患者的表皮生长因子受体衍生的肽免疫原性的鉴定。
影响因子：
8.8
作者：
通讯作者：
--
DOI：
10.1056/nejmoa1407222
发表时间：
2014-10-16
期刊：
The New England journal of medicine
影响因子：
--
作者：
Maude SL;Frey N;Shaw PA;Aplenc R;Barrett DM;Bunin NJ;Chew A;Gonzalez VE;Zheng Z;Lacey SF;Mahnke YD;Melenhorst JJ;Rheingold SR;Shen A;Teachey DT;Levine BL;June CH;Porter DL;Grupp SA
通讯作者：
Grupp SA